Heritage Pharma Announces The Return Of Tetracycline HCI Capsules

Heritage Pharma Announces The Return Of Tetracycline HCI Capsules

By Heritage Pharmaceuticals Inc.

Published: Monday, Oct. 21, 2013 - 6:09 am

EATONTOWN, N.J., Oct. 21, 2013 -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Tetracycline HCl Capsules, USP in 250 and 500 mg strengths.  This product is the AB rated generic equivalent to the antibiotic Achromycin V and adds to Heritage's robust portfolio of generic oral solid products.  Tetracycline capsules have been on the FDA drug shortage list for the past two years and Heritage is the first generic pharmaceutical manufacturer to reintroduce the product.

About Tetracycline HCl Tetracycline HCl is indicated for the treatment of various bacterial infections.  The package insert, which is available at www.heritagepharma.com, contains detailed information about the indications, complete side effect profile and prescribing information.

About Heritage Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market.  Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management.  Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.   Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.

SOURCE Heritage Pharmaceuticals Inc.

Read more articles by Heritage Pharmaceuticals Inc.

Read more here: http://www.sacbee.com/2013/10/21/5838696/heritage-pharma-announces-the.html#storylink=cpy

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.